finance.yahoo.com ·
Know Fund Sale Pharma Stock
Topic context
This topic has been covered 420725 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedA single hedge fund sold its entire position in Supernus Pharmaceuticals. This is a portfolio rebalancing event with no direct commercial mechanism affecting the company's operations, supply chain, or product pricing. The sale does not indicate any change in Supernus's business fundamentals, revenue, or margin. No scarcity or supply chain impact.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Quantedge Capital sold all 89,600 shares of Supernus Pharmaceuticals in Q1 2026.
- Transaction value estimated at $4.56 million.
- Supernus shares up 56% over the past year to $49.37 as of May 11, 2026.
- Supernus Q1 revenue grew 39% to $207.7 million.
- Supernus market cap $2.87 billion.
Related stories
fool.com
Keysight Keys Q2 2026 Earnings Transcript
proactiveinvestors.com.au
The Morning Catch Up Asx Set to Open Lower Ahead of Pivotal Nvidia Earnings
nbclosangeles.com
Spacex Confirms Plans for IPO
finance.yahoo.com
Biosig Technologies Q1 Earnings Call
zerohedge.com